JBJyotirmaya Behera

Jyotirmaya Behera

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jyotirmaya Behera has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Age-associated temporal decline in butyrate-producing bacteria plays a key pathogenic role in the onset and progression of neuropathology and memory deficits in 3×Tg-AD mice

    by Paula M. Chilton, Smita S. Ghare, Benjamin T. Charpentier, Scott A. Myers, Aakarsha V. Rao, Joseph F. Petrosino, Kristi L. Hoffman, John C. Greenwell, Neetu Tyagi, Jyotirmaya Behera, et al.

    Alterations in the gut-microbiome-brain axis are increasingly being recognized to be involved in Alzheimer's disease (AD) pathogenesis. However, the functional consequences of enteric dysbiosis linking gut microbiota and brain pathology in AD progression remain largely undetermined. The present work investigated the causal role of age-associated temporal decline in butyrate-producing bacteria and butyrate in the etiopathogenesis of AD. Longitudinal metagenomics, neuropathological, and memory analyses were performed in the 3×Tg-AD mouse model. Metataxonomic analyses showed a significant temporal decline in the alpha diversity marked by a decrease in butyrate-producing bacterial communities and a concurrent reduction in cecal butyrate production. Inferred metagenomics analysis identified the bacterial acetyl-CoA pathway as the main butyrate synthesis pathway impacted. Concomitantly, there was an age-associated decline in the transcriptionally permissive acetylation of histone 3 at lysines 9 and 14 (H3K9/K14-Ac) in hippocampal neurons. Importantly, these microbiome-gut-brain changes preceded AD-related neuropathology, including oxidative stress, tau hyperphosphorylation, memory deficits, and neuromuscular dysfunction, which manifest by 17-18 months. Initiation of oral administration of tributyrin, a butyrate prodrug, at 6 months of age mitigated the age-related decline in butyrate-producing bacteria, protected the H3K9/K14-Ac status, and attenuated the development of neuropathological and cognitive changes associated with AD pathogenesis. These data causally implicate age-associated decline in butyrate-producing bacteria as a key pathogenic feature of the microbiome-gut-brain axis affecting the onset and progression of AD. Importantly, the regulation of butyrate-producing bacteria and consequent butyrate synthesis could be a significant therapeutic strategy in the prevention and treatment of AD.


  • Open Access

    Tributyrin oral administration significantly attenuates the loss of intestinal butyrate‐producing bacteria and the ensuing cognitive dysfunction associated with Alzheimer’s Disease pathogenesis in 3xTg‐AD mice

    by Aakarsha V. Rao, Smita S. Ghare, Paula M. Chilton, Benjamin T Charpentier, Joseph Petrosino, Kristi L Hoffman, J Caleb Greenwell, Neetu Tyagi, Jyotirmaya Behera, Yali Wang, et al.

    Background: Alzheimer’s Disease (AD) development is linked to the loss of overall gut microbial diversity. However, the specific alterations are only beginning to be examined. In this regard, decreases in intestinal butyrate‐producing bacteria have been indicated by pre‐clinical and clinical studies in AD. The current work, employing the 3xTg‐AD mouse model examined the causal association of loss of butyrate‐producing bacterial communities with cognitive dysfunction associated with AD pathogenesis.Method: Cecal samples from tributyrin (TB) treated and untreated female 3xTg‐AD mice were used to perform metataxonomic analysis by sequencing the 16S rRNA gene (V4 region) on a large‐scale Illumina MiSeq platform. Inferred metagenomics analysis was performed using the PICRUSt2 pipeline. TB treatment (oral gavage, 2mg/kg, twice a week) was initiated at 6‐months of age until 17‐months. Spatial and short‐term memory functions were tested using the Y‐maze and Novel Object Recognition Test (NORT).Result: Metataxonomic analysis showed an age‐dependent, significant decline in alpha diversity represented by measures of OTUs, Chao‐1 and Shannon Index from 2‐ to 18‐months. Additionally, age‐dependent changes in gut microbial composition were demonstrated by a significant decrease in the Firmicutes‐to‐Bacteroidota (F/B) ratio. Further analysis of specific features of the gut microbiome demonstrated an age‐dependent decrease in total butyrate‐producing families within the Firmicutes phylum; particularly, a significant loss of critical butyrate producing family Ruminococcacea was identified. Predictive functional analysis using PICRUSt2 also showed a significant reduction in the abundance of specific bacterial genes involved in butyrate synthesis. Importantly, these age‐dependent markers of gut microbial dysbiosis coincided with diminished measures of spatial and short‐term memory. Notably, administration of TB, a butyrate pro‐drug, significantly attenuated the age‐dependent (i) decline in gut microbial diversity & butyrate‐producing bacteria and (ii) loss of spatial and short‐term memory.Conclusion: The findings from this study identify that decline in total butyrate‐producing families is a key pathogenic feature of AD‐associated microbial dysbiosis and cognitive dysfunction. Importantly, these findings have the potential to inform the development of treatment strategies targeting gut microbial dysbiosis using TB, to prevent onset and development of cognitive decline in AD.


  • Open Access

    Oral tributyrin supplementation attenuates Alzheimer’s disease‐associated neuropathology and prevents cognitive and behavioral deficits in the 3xTg‐AD mouse model

    by Paula M. Chilton, Smita S. Ghare, Benjamin T Charpentier, Scott A. Myers, Aakarsha V. Rao, J Caleb Greenwell, Neetu Tyagi, Jyotirmaya Behera, Yali Wang, Lucy J Sloan, et al.

    Background: Dysbiosis of the gut microbiome is associated with various diseases, including Alzheimer’s Disease (AD). A decrease in intestinal butyrate‐producing bacteria has been indicated by pre‐clinical and clinical studies in AD; therefore, we assessed the effects of long‐term oral administration of tributyrin (TB: a butyrate pro‐drug) on the development of memory and neuromuscular deficits, and CNS pathology in 3xTg‐AD (3xTg) mice.Method: Oral gavage with tributyrin (2 mg/kg) was given twice weekly to female 3xTg mice between 6‐ and 17‐months of age. Treatment was stopped and mice were tested for spatial memory (Y‐maze and novel object recognition test‐NORT) and neuromuscular function (RotaRod and grip tests). Brains from untreated (2‐, 12‐, or 18‐month‐old untreated or TB treated 18‐month‐old mice were formalin‐fixed, paraffin‐embedded for microscopic analysis of AD‐associated pathology, neuroinflammation, and oxidative stress markers.Result: Short‐term, episodic memory and spatial memory along with balance and coordination and grip strength were all significantly decreased in untreated 3xTg mice at 17‐months of age compared to 2‐ or 10‐month‐old mice. TB treatment, however, attenuated these effects in 17‐month mice. TB treatment did not affect the accumulation of either Aβ or Tau in the subiculum at 18‐months. However, pTau hyperphosphorylation—as indicated by co‐staining with both pTau(Ser404) and AT‐8 pTau (Ser202/Thr205) mAb—was effectively prevented with TB treatment. Similarly, significant age‐dependent neuroinflammation indicated by IBA1 (microglia) and GFAP (astrocytes) staining was increased in the hippocampus of 18‐month 3xTg mice and was effectively prevented by TB treatment. Additionally, markers of oxidative stress, 4‐HNE and acrolein adducts, were also increased in the molecular layer of the hippocampus and attenuated in TB treated mice.Conclusion: These studies demonstrate that TB treatment after initiation of Aβ deposition in the subiculum dramatically abrogates the loss of neurologic function in 3xTg mice as demonstrated by increased memory, cognition, and neuromuscular function. Moreover, these increases coincide with attenuated AD‐associated pathology in the hippocampus of TB‐treated 3xTg mice. Importantly, these data indicate that treatment with a butyrate pro‐drug can be integrated into treatment strategies to preserve cognitive and neuromuscular functions in patients in the prodromal phase of AD.


  • Open Access

    Exercise Improved Cognitive Impairment in Aging Mice via Skeletal Irisin

    by Jyotirmaya Behera, Jessica Ison, Neetu Tyagi

    The progressive decline of neurological learning and memory is rising as the lifespan increases in humans. The mechanistic basis of aging‐associated memory impairment is not still clearly understood. It is also currently unknown whether irisin is secreted by bone tissue after exercise or whether it regulates brain memory function via distant paracrine signaling in vivo . Here we show that age‐related suppression of irisin expression is linked with skeletal bone loss and memory disturbances in the aging brain. However, daily treadmill exercise (Ex) was found to restore the bone and memory loss in the aging mouse. To test the hypothesis, we employed young and aged male/female C57BJ/L6 wild‐type (WT), which were grouped as follows: Young (Yg, 3month);(ii) Yg+Ex(iii) Aged(Ag.18–22 month old); (iv) Ag+Ex. The selected mice were exercised for this 12‐week duration on a treadmill, with controlled speeds of 7 meters/min for the first week, 9 meters/min for the second week and 11 meters/min the following weeks for a total of 330 meters every day. The results show that treadmill exercise‐induced high levels of irisin mRNA transcript as well as protein expression in murine femoral bone tissues. This resulted in increased trabecular and cortical bone formation in aging mice (AG+EX) in vivo . On the other hand, AG+EX mice displayed an increased plasma and hippocampal level of bone‐derived Irisin (FNDC5). Interestingly, AG+EX mice showed higher behavioral proficiency and more robust long‐term and short‐term memory compared to AG mice. The mechanistic study shows that AG+EX mice display an increased irsin dependent upregulation of neuronal derived neurotropic factor (NDNF) in mouse hippocampus probably via epigenetic inhibition of H3K27me3 methylation at the promoter. Hippocampal overexpression of irisin by Lentiviral FNDC5/irisin administration rescues age‐memory impairment, whereas blockade of brain irisin attenuates the neuroprotective actions of physical exercise on memory in AG mice. Taken together, our findings suggest that physical exercise increases irisin production in bone and that an increase in paracrine irisin signaling in the brain enhances memory function in aging mice. Support or Funding Information Acknowledgment: Financial support from National Institute of Health grant AR‐067667‐NT is greatly acknowledged.